In the field of precision treatment for hormone-dependent diseases, peptide hormone drugs have always occupied an important position. Fertirelin Acetate (CAS: 106756-71-2), as a synthetic gonadotropin-releasing hormone (GnRH) analog, has shown significant value in tumor treatment and reproductive endocrine regulation due to its unique pharmacological properties, becoming one of the focuses of clinical research in recent years.
From a pharmacological mechanism perspective, fertirelin acetate precisely acts on pituitary GnRH receptors by mimicking the structure and function of endogenous GnRH, regulating the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Compared with natural GnRH, it has stronger biological activity and higher affinity, effectively inhibiting the gonadal axis function—reducing testosterone secretion in men and decreasing ovarian estrogen and progesterone synthesis in women. This mechanism provides a core target for the treatment of hormone-dependent diseases. It is worth noting that, compared to surgical castration, the effect of fetirelin acetate-mediated "medical castration" is reversible, with gonadal function gradually recovering after drug withdrawal, significantly improving the flexibility and safety of treatment.
In clinical applications, the value of fetirelin acetate has been validated in multiple studies. In the treatment of advanced prostate cancer, it effectively inhibits tumor cell growth by lowering circulating testosterone levels, becoming an important treatment option for hormone-sensitive prostate cancer. Simultaneously, this drug is also suitable for ovulation-related disorders such as hypothalamic dysfunctional amenorrhea and dysfunctional uterine bleeding in women, playing a positive role in improving reproductive endocrine disorders. Furthermore, veterinary clinical studies have found that fetirelin acetate combined with fenprostol significantly shortens the time from treatment to conception when treating follicular cysts in dairy cows, demonstrating its cross-species application potential.
Pharmacokinetic studies have shown that fertigrelin acetate exhibits good bioavailability in animal models such as mice and cows, with a clearly defined effective dose range—for example, the effective dose for superovulation induction in mice is 0.1-0.5 μg, providing an important reference for clinical dose optimization. However, it should be noted that high doses may reduce adverse reactions such as superovulation response, and the dose window must be strictly controlled in clinical applications.
As an important member of the GnRH analogue family, fertigrelin acetate offers diversified treatment options for hormone-dependent diseases due to its strong targeting, definite efficacy, and reversibility. With further clinical research, its application prospects in human reproductive medicine and precision oncology will be further expanded.
